A s a result of the improved survival of patients with heart failure (HF) and the overall rise in the prevalence of HF, 1 the number of patients in advanced (stage D) HF continues to increase, thus exceeding the limited availability of donor organs by a wide margin. 2 Initially used primarily as a bridge to heart transplantation, mechanical circulatory support is now increasingly offered as a destination therapy to patients with advanced HF in clinical deterioration who are not candidates for transplantation. Improvement in survival to 80% at 1-year postimplantation 3 has steadily followed the development of new technologies such as the continuous-flow pump, which now encompasses 99% of left ventricular assist devices (LVADs), 3 and improvements in patient and device management. Far from being a panacea, mechanical circulatory support is still fraught with challenges. Among them, post-LVAD right ventricular failure (RVF) is a major cause of morbidity and mortality.
Despite (1) overall improved outcomes and lower rates of RVF with the use of the newer, continuous-flow LVADs over pulsatile-flow devices, 4 and (2) development of clinical prediction scores to facilitate preoperative identification of patients at risk for RVF after implantation, [5] [6] [7] [8] [9] RVF still occurs in 13% to 40% of continuous-flow device. 10 LVAD function relies heavily on right ventricular (RV) function for adequate preload. Severe RVF cannot only lead to systemic hypoperfusion, multiorgan failure, and death but also to prolonged or recurrent hospitalization and poor quality of life even in less extreme cases. LVAD recipients who develop RVF have poor outcomes, [11] [12] [13] including higher perioperative, short-and long-term mortality, 5, 14, 15 and reduced survival to transplantation. 11, [13] [14] [15] [16] [17] [18] [19] [20] RVF has also been associated with higher risk of bleeding, renal failure, and hypotension, 13, 14, 19 and longer intensive care unit and hospital stays. 11, 14 In the absence of durable and safe options for RV support, preoperative characterization of RV function and appropriate patient selection is of paramount importance in improving outcomes post-LVAD. In this article, we review the current evidence for preoperative assessment of RV function and RVF risk, with focus on cardiac imaging and specifically echocardiography. To put the discussion in context, we also briefly review the definitions, incidence, and pathophysiology of RVF. Finally, we discuss challenges and suggest directions for future research.
Definition and Incidence of Post-LVAD RV Failure
Although RVF is common after LVAD implantation, the precise incidence estimates vary from 9.4% to 44% depending on the definition of RVF, the characteristics of the study population, and the type of LVAD (Table 1) . [5] [6] [7] [9] [10] [11] 13, 14, 16, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) defines RVF as (1) need of an RV assist device (RVAD), or (2) requirement of inhaled nitric oxide or inotropic therapy for >1 week any time after LVAD implantation in the presence of symptoms and signs of persistent RV dysfunction, such as central venous pressure >18 mm Hg with a cardiac index <2.3 L/min per square meter in the absence of elevated left atrial or pulmonary capillary wedge pressure (>18 mm Hg), cardiac tamponade, ventricular arrhythmias, or pneumothorax. 33 Most studies have used a variation of this definition combining clinical findings and hemodynamics (Table 1) . Severe RVF requiring RVAD has been reported in 9.4% to 23.4% of patients, 8, 21, 22 whereas definitions incorporating need for inotropes yield estimates ranging from 20.2% to 40%. [5] [6] [7] 13, 14 Although the need for placement of an RVAD might be viewed as an indicator of more definitive RVF, the outcomes of patients presenting with RVF, defined as the need for prolonged inotropic or other support besides RVAD, are equally unfavorable ( Table I in the Data Supplement) . Therefore, it would be important to include need for prolonged (or delayed) inotrope use when defining RVF. In this respect, following the current INTERMACS scheme for RVF severity might be reasonable. This scheme suggests that RVF be reported as (1) severe, if RVAD was implanted; (2) moderate, when inotropes or intravenous or inhaled pulmonary vasodilators were used for >1 week at any time after LVAD implantation; and (3) mild, when a combination of ≥2 symptoms and signs are present (central venous pressure >18 mm Hg, cardiac index cardiac index <2.3 L/min per square meter, ascites, moderate-to-severe peripheral edema, or echocardiographic or physical examination evidence of elevated central venous pressure) but without the need for RVAD or prolonged inotropic or vasodilator support. The latter category would not be reported in a dichotomous definition of RVF. These more granular definitions incorporate prolonged use of inotropes, which is clearly associated with adverse outcomes, and facilitate comparison between studies and reporting the effect of RVF on outcomes according to RVF severity.
Of note, no large study to date has prespecified a time frame for RVF (eg, 30 or 90 days). This would be important for consistency, which would facilitate a more valid comparison of rates and predictive modeling. In a recent large series, 34 the time to unplanned RVAD insertion ranged from 1 to 66 days after LVAD surgery, and only 4 out of 44 patients required RVAD support later than 10 days post-LVAD. Other groups have reported similar findings. 13 However, data on the incidence and impact of RVF after the 90-day window are limited. Finally, quantitative RV function has not been incorporated into RVF definitions to date.
Pathophysiology of Post-LVAD RV Failure
The pathophysiology of RVF post-LVAD is not well understood. Implantation of an LVAD promotes rapid and dramatic changes because cardiac output is largely restored and left ventricular (LV) filling pressures are relieved. This in turn leads to an increase in RV preload and a decrease in RV afterload. 35 The immediate decrease in RV afterload, however, is mostly the result of reduced LV filling pressures, 36, 37 and the observed immediate reduction in pulmonary vascular resistance (PVR) is primarily the result of increased cardiac output. 36 Reversal of structural changes in the pulmonary vasculature (previously considered fixed pulmonary hypertension) and further reduction in PVR may also occur but take more time to realize. 38, 39 In the interim, the acute rise in venous return in conjunction with perioperative transfusion and intravenous fluid administration may further strain the RV, thus increasing wall stress and exacerbating tricuspid regurgitation (TR). 40 Alterations in hemodynamics only partially explain changes in RV function post-LVAD. The LVs and RVs are interdependent by virtue of the interventricular septum, interlacing muscle fibers, and the pericardium. 41 The effects of LVAD support on the septum and RV function have been controversial. In animal studies, LVAD support induces ischemia of the septum with decreased thickening 42 and altered septal geometry. 43 However, in other animal models, septal shift did not affect RV function. 44 However, it is difficult to extrapolate findings ACEI indicates angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BiVAD, biventricular assist device; BP, blood pressure; BTT, bridge to transplantation; BUN, blood urea nitrogen; CRITT, central venous pressure-RV dysfunction-preoperative intubation-severe tricuspid regurgitation-tachycardia; CVP, central venous pressure; DT, destination therapy; IABP, intra-aortic balloon pump; INR, international normalized ratio; ITT, intention to treat; LVAD, left ventricular assist device; NO, nitric oxide; OR, odds ratio; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RV, right ventricle; RVAD, right ventricular assist device; RVF, right ventricular failure; RVSWI, right ventricular stroke work index; and TR, tricuspid regurgitation. March 2014 from healthy animals to humans with HF. In a study of 76 recipients with continuous-flow LVAD, persistent leftward bowing of the septum 30 days postimplantation was associated with significantly worse outcomes at 90 days. 45 In an in silico cardiovascular-respiratory system model, increased LVAD pump speeds seem to reduce septal contribution to RV and LV ejection and increase RV work. 46 Finally, patients with more severe RV dysfunction may be more prone to LV suction with higher LVAD pump speeds. 47
Challenges in RVF Risk Prediction
Although preoperative assessment of RV function with contemporary imaging has a strong potential to improve RVF risk prediction, there are 4 major challenges. First, a host of intraoperative events may impair RV function, including increased PVR secondary to suboptimal ventilation and alveolar hypoxia, hyperinflation, or atelectasis; acidosis causing ischemic injury; direct RV ischemia by injuring previous bypass grafts; and ischemia attributable to prolonged cardiopulmonary bypass, bleeding, transfusions, or shock. 13, 48 Second, varying practices in concomitant procedures during LVAD implantation may also alter the course of RV function. For example, there is growing evidence that concomitant tricuspid valve repair (or replacement) for severe TR results in improved RV function postimplantation. 49 Third, there is wide interinstitutional variation in the use and duration of inotropes and the threshold for RVAD support after LVAD surgery. For example, extended (≥14 days) inotropic support after LVAD surgery ranged from <15% 13, 32 to >30% 10 in recent continuous-flow LVAD series. Fourth, the population of LVAD recipients is a moving target. 2 Because post-LVAD outcomes continue to improve, there is a clear trend toward more elective implantations in less sick patients over time, 3 with destination therapy becoming rapidly the most frequent indication. 3 Also, because LVAD technology evolves, new target populations may be identified.
Despite the aforementioned challenges and potential confounders, preoperative RV function has been identified consistently as a predictor of postimplantation RVF. Several studies have considered preoperative clinical variables and cardiac imaging (ie, echocardiography) as a means to better risk stratify recipients with LVAD for RVF. In the following section, we review the available evidence, primarily focusing on echocardiography.
Risk Prediction Models and Risk Factors for RV Failure

Clinical Scores
Current RVF prediction scores rely on HF severity, laboratory evidence of end-organ damage, right heart hemodynamics, and history of cardiac procedures as surrogates of preoperative RV dysfunction (Table 2) . [5] [6] [7] [8] [9] 13 Importantly, these models have been derived from retrospective studies in patients with mostly pulsatile-flow LVADs and thus do not fully represent the current LVAD population. The predictors considered vary significantly across studies, as do definitions of RVF. Of note, preoperative risk factors for worse post-LVAD outcomes are also risk factors for RVF; that is, clinical HF status, high RV filling pressures, and low RV stroke work index. The application of RVF prediction scores in clinical practice has been limited partially because of modest score performance, and only the Michigan score has seen some uptake in research and practice. Developed in 197 recipients with LVAD (94% bridge to transplantation; continuous-flow device in 28), of whom 68 (35%) recipients developed RVF, 6 the score incorporates preoperative vasopressor requirements, liver enzyme elevations, and creatinine levels as predictors of RVF. The c statistic in the deviation cohort was 0.73. 6 However, in a retrospective study investigating the incremental value of quantitative RV parameters, 10 the Michigan score had only modest discrimination (c=0.66) for RVF prediction. In a small validation study in recipients with continuous-flow LVAD, no score predicted the need for RVAD. 50 Our group has retrospectively assessed RVF scores in 69 recipients with continuous-flow LVAD and observed that, although the Michigan score offered the highest discrimination (c=0.64), all scores had modest performance and low predictive values. 51 Of note, despite several studies investigating various echocardiographic RV function parameters, no score has incorporated quantitative RV parameters to date.
Hemodynamic Parameters Invasive Assessment of RV Systolic Function
Although RV ejection fraction can be derived by fluoroscopy, this method is rarely used in practice. Alternatively, right-sided hemodynamics allows inference of RV function. RV stroke work index, defined as (mean pulmonary artery pressuremean right atrial pressure)/stroke volume index, has been considered in several studies 11, 13, 21, 22, 24 but has not been uniformly shown to predict RVF in multivariate analyses. 9, 10, 13, 22 Potential drawbacks of RV stroke work index are (1) being a derivative of multiple measures and thus more prone to error, and (2) dependence on preload. 52 Also, the use of serial RV stroke work index for follow-up after LVAD implantation is limited.
Pulmonary Vascular Resistance and Pulmonary Artery Systolic Pressure
Although long-term unloading of the LV can lead to clinically relevant reductions of PVR and potentially restore candidacy for transplantation, 38 elevated preoperative PVR has been identified as an independent predictor of RVF 5 although not consistently. 10 It is interesting that in several studies, preoperative PVR did not emerge as a predictor of RVF. 6, 8, 13 This may be related to the fact that PVR is highly dependent on cardiac output and is therefore dramatically affected by LVADinduced increases in cardiac output. Low pulmonary artery systolic pressure (PASP) has been considered a surrogate of severe RV dysfunction in advanced HF and has been associated with post-LVAD RVF in early studies. 21, 22 However, this is probably seen only in the extreme end of RV dysfunction. In contemporary studies, low PASP was either a weak predictor 6 or did not confer useful predictive information. 5, 10, 13 This is probably because (1) PASP is a function of both PVR and RV systolic function, and, thus, various combinations of these parameters can yield similar PASP values, blunting discrimination for RV dysfunction; and (2) LVAD support is now offered to an HF population with a smaller proportion of patients with extreme RV dysfunction from the outset, and hence the predictive ability of low PASP is less relevant.
Echocardiography
Accurate determination of RV function with transthoracic echocardiography has proven to be challenging, secondary to the retrosternal position of the RV and its complex geometry. The RV inflow and outflow tracts are out of plane and difficult to image simultaneously. Postimplantation changes and device-related artifacts further limit post-LVAD visualization and measurements. Despite these challenges, echocardiography is still the most available, feasible, affordable, and safe imaging modality for patients with advanced HF. However, RV contractility is often subjectively classified into normal or mildly, moderately, or severely reduced. This semiquantitative approach has poor reproducibility, accuracy, and sensitivity to detect clinically relevant changes. The American Society of Echocardiography has recently provided guidelines for objective, quantitative assessment of RV function. 53 In Table 3 , we summarize the available data on the predictive value of quantitative RV parameters in LVAD populations for RVF prediction. 10, 23, 24, [26] [27] [28] [30] [31] [32] 
M-Mode Parameters
Normal RV function is highly dependent on longitudinal shortening. 53 A simple approach to study RV longitudinal function is to place an M-mode cursor on the tricuspid annulus in an apical RV view and measure longitudinal annular displacement. Tricuspid annular plane systolic excursion (TAPSE) should be ≥1.6 cm in adults. 53 Low TAPSE has been associated with worse survival in pulmonary arterial hypertension. 54, 55 However, TAPSE is a regional, linear parameter for a complex structure and is dependent on loading conditions and insonation angle (Figure 1) . Although TAPSE has been reported to predict RVF in a small early study, 23 this finding has not been confirmed in subsequent LVAD cohorts. 10, 27, 28, 30 2-Dimensional Parameters RV fractional area change (RVFAC) is a feasible quantitative alternative to eyeballing RV systolic function and correlates well with cardiac MRI measurements. 56, 57 An RVFAC <35% is considered abnormal. 53 A >10% reduction in RVFAC at 1 month was associated with worse quality of life and poor exercise capacity in patients with an LVAD. 58 However, the reproducibility and prognostic value of RVFAC in patients with LVAD is uncertain because the available studies report suboptimal quality of assessments and fair correlation coefficients for observer variability (0.50-0.76). 58, 59 Heavy trabeculation and pacemaker or defibrillator lead artifacts are common challenges when evaluating RVFAC in patients with advanced HF (Figure 2) . In a small retrospective study that included planned RV support in the definition of RVF, 30 lower RVFAC predicted RVF. However, RVFAC did not predict RVF in another larger study 28 and was only marginally or not predictive in other retrospective studies. 10, 23, 27 The size of the RV, mainly in the form of RV/LV diameter ratio, is surrogate of RV contractility and in some studies demonstrated strong association with RVF. 27, 32 Other studies, however, failed to confirm this finding. 10, 30 The main challenge with the RV/LV diameter ratio is the standardization of the acquisition plane and level (basal, mid, apical). In a study specifically assessing reproducibility of the RV/LV diameter ratio, 28 the intra-and interobserver interclass correlation coefficients were 0.57 and 0.61, respectively.
Doppler and Tissue Doppler-Based Parameters
Although severe TR has been identified as a strong predictor of RVF in some studies, 9, 16, 24 other large studies did not find such an association. 6, 10 Shorter TR duration, presumably a marker of early equalization of RV and atrial pressures, was associated with worse outcomes in a cohort of recipients with continuous-flow LVAD. 26 However, TR has not been uniformly evaluated in studies investigating RVF predictors, 5, 13 including echocardiography-focused studies. 31 Recently, tricuspid annular dilation assessed by transesophageal echocardiography was identified as a predictor of midterm post-LVAD survival among patients without preoperative severe TR. 29 Despite the strong association with RV dysfunction in the general HF population, TR may not be a suitable marker of RV function in contemporary candidates with LVAD. First, the majority of these patients have previously received an implantable defibrillator with or without cardiac resynchronization capability. 60 Pacemaker and defibrillator lead cause or worsen TR in a considerable proportion of recipients. 61 Although the clinical implications of lead-induced TR are still unclear and severe TR is uncommon, this effect nevertheless blunts the value of TR as an RV function surrogate. Second, a growing number of recipients with LVAD undergo simultaneous procedures for severe TR, thus confounding the use of TR as a predictor of RVF.
Tissue Doppler imaging is an attractive alternative to TAPSE because myocardial velocities are easy to obtain and reproduce. Systolic velocity of the tricuspid annulus reflects longitudinal RV function. However, velocities depend on insonation angle and loading conditions (Figure 3 ). Also, translational motion of the heart and tethering by adjacent diseased myocardial segments can produce velocities that are not representative of the performance of the interrogated segment. In a study of 68 recipients with LVAD, systolic tricuspid annular velocity did not predict RVF. 31 The myocardial performance index (MPI), defined as the ratio of isovolumic time divided by the ejection time, 53 is considered an indicator of global RV function. An RV MPI >0.40 by pulsed-wave Doppler or >0.55 by tissue Doppler indicates RV dysfunction. 53 Longer isovolumic phases and shorter ejection time signify worse ventricular performance as expressed by a higher MPI. Although the MPI is fairly independent of heart rate and geometry, it is highly sensitive to loading conditions and less reliable with elevated right atrial pressures. 53 Data are largely lacking, but in a small study, the RV MPI was not a predictor of RVF postimplantation. 23 
RV Mechanics
Strain expresses myocardial shortening or lengthening (in the longitudinal and circumferential directions) or thickening or thinning (in the radial direction), whereas strain rate is the rate of deformation over time. Strain and strain rate, collectively termed ventricular mechanics, reflect myocardial performance and provide a more direct assessment of myocardial contractility over ejection fraction or linear measurements. These indices may be calculated from either tissue velocity measurements (tissue Doppler imaging) or tracking of unique ultrasound speckles from frame-to-frame 2-dimensional (B-mode) images. Strain and strain rate are independent of ventricular morphology and are angle independent when obtained by speckle tracking. However, strain measurements are intrinsically load dependent. The American Society of Echocardiography does not currently recommend tissue Doppler imaging-based regional RV mechanics because of high variability, lack of standardization, and paucity of normative data. 53 Speckle tracking represents a promising alternative attributable to (1) automated myocardial delineation and tracking, and (2) insights into regional myocardial performance ( Figure 4 ). 53, 62, 63 The literature reporting on RV function using speckle tracking is growing. In a retrospective study of 117 patients undergoing LVAD implantation, RV free-wall longitudinal strain by velocity vector imaging (a variant of speckle tracking using standard Digital Imaging and Communications in Medicine images) predicted RVF with 76% specificity and 68% sensitivity at a cutoff of −9.6%. 10 In this study, RVF (defined as the need for RVAD or inotropic agents for >14 days) was encountered in 47 patients (40%). RV free-wall strain was a predictor of RVF in models including the Michigan score and had incremental predictive value, increasing the C statistic from 0.66 to 0.77 (P<0.01) and improving net reclassification. 10 In another study of 68 patients undergoing elective LVAD surgery, RV longitudinal strain by speckle tracking was significantly impaired preoperatively (-12.6±3.3% versus -16.2±4.3%; P<0.001) in 24 patients (35.3%) who experienced RVF by 14 days. 31 Other groups have recently reported similar findings. 64, 65 Although the American Society of Echocardiography does not currently recommend speckle-tracking parameters as a clinical tool secondary to cross-platform standardization issues and lack of definitive data, we believe that global and free-wall longitudinal RV mechanics (strain and strain rate), preferably assessed by speckle tracking, are probably the most promising approach for RVF prediction. Strain and especially strain rate are less sensitive to loading conditions and represent systolic RV function reasonably well. 66 Also, the consistency of findings on the predictive value of longitudinal RV mechanics for RVF across different research groups is promising. 10, 31, 64, 65 Of note, post-LVAD assessment of RV mechanics is feasible, 31 hence facilitating tracking of RV function, and adds information incremental to that obtained from preoperative imaging. Figure 1 . A, In patient (ischemic etiology), the interventricular septum demonstrates low peak strain (normal values: −14±4% to −22±5% from base to apex) 62 suggestive of severe systolic dysfunction, whereas the RV free-wall demonstrates preserved systolic function, especially at the basal and middle segments (lower reference values: −18% to −20%). 53,63 B, In patient (nonischemic pathogenesis), the low peak strain values across all segments and the low global strain (−4.3%) suggest severe global RV systolic dysfunction. Note also the fragmented systolic activation in the linearized map (lower left) in B as compared with the more homogenous activation in A.
Other Imaging
Multidetector computed tomography has been successfully used to visualize the LVAD cannulae and detect postoperative complications. 67 In recipients with LVAD, RV ejection fraction by multidetector computed tomography was highly reproducible and correlated well with RVFAC. 59 However, data with multidetector computed tomography in patients with LVAD are limited. Also, the need for nephrotoxic contrast precludes routine use of multidetector computed tomography in candidates with LVAD, who often have concomitant kidney disease.
Conclusions and Future Directions
RV failure remains a challenge in the era of continuous-flow LVADs. Beyond the inherent challenges in the assessment of RV function, intraoperative events, concomitant surgical procedures, and postoperative changes in pulmonary hemodynamics and device settings may confound the ability of preoperative assessment of RV function to predict RVF. Additional challenges include evolving mechanical circulatory support technology and shifts in the target population. However, the full potential of contemporary imaging, especially echocardiography, has not been fully used in the preoperative assessment of candidates with LVAD. In this direction, we believe that the following issues should be a priority.
Standardization of Echocardiographic Protocols
Preoperative RV function is still assessed subjectively in many patients. Therefore, an important first step would be the standardization of echocardiographic protocols before and after device implantation across LVAD centers. This would be greatly facilitated if the INTERMACS registry included a dedicated echocardiographic module; the currently required data are rudimentary (semiquantitative valvular regurgitation, LV ejection fraction, LV end-diastolic diameter). A common module for all centers could include quantitative data on LV and RV structure and function and a standard set of Doppler-based hemodynamics. A pilot RV mechanics module for centers able to contribute mechanics data could also be launched and expanded over time.
Refinement of RVF Definition and Serial Assessment of RV Function
Currently, the definition of RVF does not include any parameters of RV function. One way to incorporate RV systolic function parameters would be to require several echocardiographic criteria for RVF, for example, the presence of 2 out of 4 standard predefined RV dysfunction criteria (low TAPSE, low RVFAC, low tricuspid s', or high right ventricular index of myocardial performance, using the American Society of Echocardiography cutoffs) in addition to hemodynamic criteria and signs/symptoms. This could increase the specificity to overcome the challenges associated with single parameters as discussed above. A single parameter might be misleading, but if multiple parameters point to the same direction, then chances are that true RV dysfunction is highly likely. In fact, in delayed RVF cases when central lines have already been removed, the RV dysfunction criteria might be used in lieu of hemodynamics. These parameters are feasible to measure in the postoperative period. 31 In the same sense, quantitative RV systolic function parameters can be used to track RV function over time postoperatively and potentially track the effect of afterload-reducing agents on RV function. Also, longer-term serial assessment of RV function would be important because pulmonary hemodynamics change over time post-LVAD placement. 39 
Merging Research and Practice
The entire field is moving fast. Therefore, it is important for research and practice to converge. For example, it would be important for every center to acquire its own experience with echocardiographic parameters and communicate the results and outcomes with the LVAD team. From a practical perspective, we believe that based on the current data, it would be reasonable to cautiously re-evaluate candidacy for LVAD, and perhaps consider alternatives, for patients with an absolute value of RV free-wall or global strain of <10%, especially in conjunction with clinical surrogates of RV dysfunction. 10 In the same spirit, leveraging INTERMACS would be the fastest avenue forward. The derivation and validation of predictive models based on clinical and echocardiographic variables in the INTERMACS database would (1) leverage existing infrastructure, (2) ensure multicenter input and applicability of results, and (3) allow for regular updating of selection algorithms as both technology and target population evolve. 
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